Anticipate FDA feedback on clinical hold for AMR in Q2, 2025. Target IND submission for Aplastic Anemia in Q2, 2025. Report the interim data from the ongoing ITP phase 1 study in mid-2025. Anticipate finalizing the equity transfer agreement regarding Precision Autoimmune Therapeutics in Q2 2025. Upon completion of this transaction, CASI will have the sole global ownership of all indications in CID-103.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI: